Quinoline

Quinoline

SCHEMBL4747553

CC(C)[C@H](N)C(=O)O.c1ccc2ncccc2c1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
SLC7A5 Q01650 1/20 0.48
NPSR1 Q6W5P4 2/20 0.44
RXFP1 Q9HBX9 2/20 0.44
KDM4E B2RXH2 2/20 0.44
PRNP P04156 1/20 0.44
MAPK10 P53779 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
PABPC1 P11940 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
PLK1 P53350 1/20 0.41
ADORA2A P29274 3/20 0.40
CYP3A4 P08684 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoline SCHEMBL7081987 0.90 ALDH1A1 (0.59) ALDH1A1NPSR1RXFP1KDM4EPRNP
Quinoline SCHEMBL7081988 0.90 ALDH1A1 (0.59) ALDH1A1NPSR1RXFP1KDM4EPRNP
Valine SCHEMBL2205229 0.85 SLC7A5 (0.50) ALDH1A1SLC7A5KDM4ESMN1; SMN2LMNA
Quinoline SCHEMBL5874375 0.85 ALDH1A1 (0.61) ALDH1A1NPSR1RXFP1KDM4EPRNP
Quinoline SCHEMBL27820159 0.85 ALDH1A1 (0.61) ALDH1A1NPSR1RXFP1KDM4EPRNP
Quinoline SCHEMBL5874361 0.85 ALDH1A1 (0.61) ALDH1A1NPSR1RXFP1KDM4EPRNP
Phenazine SCHEMBL28881744 0.84 SLC7A5 (0.58) ALDH1A1SLC7A5NPSR1RXFP1KDM4E
Quinoline SCHEMBL4265433 0.83 ALDH1A1 (0.68) ALDH1A1KDM4ESMN1; SMN2LMNAALOX15
Quinoline SCHEMBL11151476 0.82 ALDH1A1 (0.74) ALDH1A1KDM4ESMN1; SMN2LMNAALOX15
Quinoline SCHEMBL2201840 0.82 ALDH1A1 (0.74) ALDH1A1KDM4ESMN1; SMN2PABPC1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008130319-A2 NOVEL N-TETRAHYDRONAPHTALENE OR N-CHROMANE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
WO-2008130321-A2 NOVEL N-TETRAHYDRONAPHTALENE OR 5-HETEROCYCLYL-CHROMANE OR 8-HETEROCYCLYL-TETRAHYDRONAPHTALENE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
CN-100379735-C 1,2,3,4,7, 8-hexahydro-6H- [1,4] diazepino [6,7, 1-IJ ] quinoline derivatives as antipsychotic and antiobesity agents WYETH CORP (US) 2008-04-09 CN disclosed
CN-1955180-A 1,2,3,4,7,8-hexahydro-6H-[1,4]diazepino[6,7,1-IJ] quinoline derivatives as antipsychotic and antiobesity agents WYETH CORP (US) 2007-05-02 CN disclosed
EP-1497294-B1 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS WYETH CORP (US) 2007-03-28 EP disclosed
US-20060154920-A1 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents WYETH (US) 2006-07-13 US disclosed
US-7071185-B2 1,2,3,4,7,8-hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents WYETH (US) 2006-07-04 US disclosed
CN-1662534-A 1,2,3,4,7, 8-hexahydro-6H- [1,4] diazepino [6,7, 1-IJ ] quinoline derivatives as antipsychotic and antiobesity agents WYETH CORP (US) 2005-08-31 CN disclosed
EP-1497294-A1 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS Wyeth (US) 2005-01-19 EP disclosed
US-20040019040-A1 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents WYETH 2004-01-29 US disclosed
WO-2003091251-A1 1,2,3,4,7,8-HEXAHYDRO-6H-[1,4]DIAZEPINO[6,7,1-1J]QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS WYETH (US) 2003-11-06 WO disclosed
US-5576338-A ANTIALLERGENS, ANTIHISTAMINES, ANTIINFLAMMATORY AGENTS AND CYTOPROTECTIVE AGENTS FOR CARDIOVASCULAR DISORDERS MERCK FROSST CANADA, INC. (CA) 1996-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154920-A1 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents HTR2C, HTR7, HTR1A ALDH1A1 954/4885SLC7A5 757/4885NPSR1 128/4885
US-20040019040-A1 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents HTR2C, HTR1A, HTR7 ALDH1A1 852/4885SLC7A5 704/4885NPSR1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.